2021
DOI: 10.1016/s2213-2600(21)00084-9
|View full text |Cite
|
Sign up to set email alerts
|

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

6
187
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 151 publications
(193 citation statements)
references
References 26 publications
6
187
0
Order By: Relevance
“…ORR (primary endpoint) was 42.9% (95% CI: 31.1, 55.3). 32 Individual TRAEs occurring in > 25% of patients were reported by Lu et al 32 Of the 70 treated patients, all (100%) reported TRAEs. 32 The most common TRAE was peripheral edema in 54% of patients (grade ≥ 3 in 9%).…”
Section: Savolitinibmentioning
confidence: 93%
See 1 more Smart Citation
“…ORR (primary endpoint) was 42.9% (95% CI: 31.1, 55.3). 32 Individual TRAEs occurring in > 25% of patients were reported by Lu et al 32 Of the 70 treated patients, all (100%) reported TRAEs. 32 The most common TRAE was peripheral edema in 54% of patients (grade ≥ 3 in 9%).…”
Section: Savolitinibmentioning
confidence: 93%
“…9,14 Interim data from a Phase II study in 70 patients with METex14 skipping NSCLC have been reported (Table 1; NCT02897479). 32 Patients received 600 mg or 400 mg savolitinib once daily in 21-day cycles; median duration of treatment was 6.9 months (interquartile range, 2.2 to 13.8) or 6.5 months (2.7 to 10.5), respectively; for 600 mg, three dose reductions were allowed (400 mg, then 300 mg, then 200 mg, all once daily) and for 400 mg, two dose reductions were allowed (300 mg then 200 mg, both once daily). For the 70 patients in the full analysis set, median age was 69 years (range: 65 to 75), 59% were male, 60% had never smoked, 83% had an ECOG-PS of ≥ 1, 57% had adenocarcinoma, whilst 36% had pulmonary sarcomatoid carcinoma, and 21% had brain metastases at baseline.…”
Section: Savolitinibmentioning
confidence: 99%
“…The ORR of savolitinib‐treated group was 42.9%, with a median PFS of 6.8 months and a median OS of 12.5 months. 84 …”
Section: Targeted Therapy For Nsclcmentioning
confidence: 99%
“…The efficacy and safety of savolitinib 600 mg (bodyweight ≥ 50 kg) or 400 mg (bodyweight < 50 kg) in unresectable or metastatic MET ex14 NSCLCs (40 (57%) with adenocarcinoma, 25 (36%) with PSC and 5 (7%) with other NSCLC subtypes) were assessed in a multicentre, multi-cohort, single-arm phase II study [ 106 ]. At a median follow-up of 17.6 months, the IRC-assessed objective response rate was 42.9% (30 of 70 patients).…”
Section: What Are the Preferred First-line And Subsequent Therapies For Patients With Advanced Nsclc Harbouring Met Exmentioning
confidence: 99%